The US firm’s lead antibody biopolymer conjugate asset failed to match Regeneron/Bayer’s Eylea in two Phase III diabetic macular edema studies, prompting discontinuation of the program and a reassessment of an earlier program based on the same platform technology.

Monthly dosing remains a possibility in wet age-related macular degeneration, though diabetic macular edema and retinal vein occlusion look more promising.

Five notable studies are expected to report top-line data in the first quarter. With the help of Biomedtracker's Early 2022 Outlook Report, we take a look at the major catalysts likely to kick off the year, including in heart failure and wet AMD.

Adverum said it would cease developing ADVM-022 for DME and focus on wet AMD, but the adverse events that prompted the shift could invite further scrutiny in an already competitive market.